Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.

Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.

http://www.wikidata.org/entity/Q35051942

about

New approaches for precise response evaluation in hepatocellular carcinoma How I do it: Cone-beam CT during transarterial chemoembolization for liver cancer Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis Assessment of response to therapy in hepatocellular carcinoma Reassessing hepatocellular carcinoma staging in a changing patient population.Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib.Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.Research reporting standards for radioembolization of hepatic malignancies.Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times.Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma Radioembolization for primary and metastatic liver cancer.Imaging for assessment of treatment response in hepatocellular carcinoma: Current update.Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients.Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.Transcatheter intraarterial therapies: rationale and overview Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression.Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives.Perspectives on the design of clinical trials combining transarterial chemoembolization and molecular targeted therapy.Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular carcinoma Chemoembolization and radioembolization for hepatocellular carcinoma.Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.Assessment of the treatment response of HCC.Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques.Imaging tumor response following liver-directed intra-arterial therapy.Treatment of intermediate-stage hepatocellular carcinoma.Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.Hepatic imaging following intra-arterial embolotherapy.NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017 Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection.Parametric response mapping of dynamic CT: enhanced prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.

P2860

Q26866367-7E07D125-EA5A-4CA4-AB25-97A5AA08E5BC Q28087066-975F897A-8E7B-48EF-838B-9FD933EE2622 Q28314897-778F681A-4216-457C-9A68-5B258490497C Q28831507-38E51A67-7D90-44D5-B6AF-DC8B12D48842 Q33560982-2B483109-C326-44F6-AE8D-1902320941DE Q33767286-8E2E33FF-B02A-463B-9FBA-83720910971E Q34065128-59EC0D2E-03A3-454F-A6ED-CBDFF07911FA Q34168811-C8A52302-BBC3-40C2-9E75-7C154A1B8F2E Q34681150-6E2F8B99-5470-491A-A984-4439F9E8861F Q34982068-27E61241-3C18-48DB-AE11-9BCA44B5A4FD Q35073497-E85E5445-1A8C-4C68-BFBE-4E6E74F55C7E Q35085486-64DE307A-5112-4BA8-8F94-D64B7D4D0D63 Q35111887-E4D3D1CE-453D-4AC3-9508-5FDB6E98245A Q35154103-5A7E98DF-31DC-4D87-AA70-3EE7D730EBF5 Q35203257-8E509FE1-7041-491D-A2EC-1F5F89310196 Q35564038-6836EACE-4949-40BC-99DC-D9625E4EE80B Q35568722-CAFA4452-CC7C-4C44-8941-5FBFB4FB5871 Q35731141-157146FC-893C-4661-95F7-EC7A8B295A1B Q35815482-A56F5CCF-125A-498C-9127-AD7E36727433 Q35821594-0FC208C2-BF2A-4529-8591-8FCBA2BB6AA7 Q35877902-10242581-349F-4FA1-AAAA-DB3C08188A93 Q35894925-FC0B1A2A-C832-4B1E-8E0B-023891832040 Q36104314-E0705B93-E215-4CED-BDBF-40CA2355C3B9 Q36416250-337869B7-E1D7-423A-9AF5-265BF52011A7 Q36481071-328CB25C-274C-45A2-B5F2-5707DC72DE80 Q36482781-D7BA7720-71D8-4139-B372-BA461877E520 Q37068157-3E311950-1B73-49C6-A3D0-A898AA90A425 Q37140678-508BBC91-C8A1-489D-ADCC-A978CC1F8DAD Q37143017-88EEA662-CAA7-4E09-B083-13886930DFC2 Q37238192-3AC1D194-7733-475C-82AB-6CFD16BCACB3 Q37339616-EADD459A-6551-477C-B213-115457DCB131 Q37833521-B454F875-3A3D-404B-8DD5-93884E24B4C2 Q37935712-2866C3E7-F9AB-4499-9DDE-FC33E98E799A Q38117579-1B91059D-6E66-408F-961F-2FAA19416D8C Q38236876-ADF17BE2-7AC9-48DB-8F91-E9AA91486D3D Q38265024-AE8BF540-0E80-424D-A964-11D01749E5C4 Q38716483-1D79ACAF-7F66-4CD2-B5F7-4C32AC28BF6A Q38801422-C656E0A6-3C27-43E0-ACBF-6D674193DE6E Q40091767-EB7AB37D-68DB-4388-9F60-033F2323FE45 Q40333754-36D904C1-C8C6-4236-9150-A4CCE4AFB886

P2860

Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.

http://www.wikidata.org/entity/Q35051942

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Imaging response in the primar ...... for hepatocellular carcinoma.

@ast

Imaging response in the primar ...... for hepatocellular carcinoma.

@en

type

label

Imaging response in the primar ...... for hepatocellular carcinoma.

@ast

Imaging response in the primar ...... for hepatocellular carcinoma.

@en

prefLabel

Imaging response in the primar ...... for hepatocellular carcinoma.

@ast

Imaging response in the primar ...... for hepatocellular carcinoma.

@en

P1433

Q35051942-B730D64B-C308-4630-B7A0-5B9DC9752978

P1476

Q35051942-DCF089A3-F927-4EC9-81EA-223F07CB4BBB

P2093

Q35051942-06517713-2C54-4A93-827A-6DD0FC246B75

Q35051942-1738F11F-7DB4-47A0-B835-337A82719D28

Q35051942-195E45C3-8A88-4195-A0AA-F152BD0CD77E

Q35051942-32C4D344-C5EE-4A8D-90E5-5EE93B067CA8

Q35051942-4AAB80F4-D8A5-4E13-BEBE-55E809EE6CF0

Q35051942-6C501A30-6F16-41E7-ADED-2F17C6C1CFBA

Q35051942-75417E89-1AA7-4198-92C5-91B8770F7EF9

Q35051942-8BFD18F6-D5C8-4181-97E3-63761A9401FE

Q35051942-8D66E6B7-2B31-473D-8601-FDAD08EDCD9E

Q35051942-A5DD2CAE-47F5-4F47-BE47-80F828D437D7

P2860

Q35051942-1126D8B8-E692-4CF2-8BC7-46A57C5DE5A0

Q35051942-155C664E-49DB-45D7-8C61-CAB2770F0576

Q35051942-17069FD3-47E0-4637-B9E7-220D12FF3A05

Q35051942-1E138A83-BFA0-438C-8F8F-573B85A1D1CB

Q35051942-20490215-A194-4013-AB6A-DE9D59171847

Q35051942-2072CB2C-6A62-4A7F-833A-E137119017E7

Q35051942-22733EE1-8BB9-473A-8A94-834430796737

Q35051942-371CFA61-C539-4CA8-B60D-A5537AFBD20D

Q35051942-3D91DF55-9854-47E4-A4B8-459A7FC303B5

Q35051942-47731D37-4195-4FB8-B075-D88FD0FC4EBF

P304

Q35051942-852A9143-9D0E-4DAA-B33F-EACFF5C15535

P31

Q35051942-6C85DFA3-C975-4F4C-B3E4-3BFF441A13C4

P356

Q35051942-53D21D4C-80AB-40D9-84C2-C3164B636B3B

P407

Q35051942-BBC85578-137C-440E-96C7-6DDF305D3B9A

P433

Q35051942-376F0D96-7562-4236-8F13-950FEDFA5082

P478

Q35051942-332C0BC5-18D4-491E-B956-14AB7F063DF1

P50

Q35051942-4931612B-E934-4052-8CDB-9C772DF2F7F8

Q35051942-5A133779-EC43-485F-9EF2-1ED6608757DF

P577

Q35051942-40729C5B-9F8D-41CA-8242-A5542746F30C

P5875

Q35051942-340A443A-B767-4A40-AE0B-54B024B33729

P698

Q35051942-7BC4285C-C2DC-4EEF-93F1-35CB2046173F

P932

Q35051942-B38F47D7-28B7-4F50-BACA-C25AFCBFF0A0

P356

P1433

Journal of the American Medical Association

P1476

Imaging response in the primar ...... for hepatocellular carcinoma.

@en

P2093

Al B Benson

http://www.w3.org/2001/XMLSchema#string

Albert A Nemcek

http://www.w3.org/2001/XMLSchema#string

Ed Wang

http://www.w3.org/2001/XMLSchema#string

Frank H Miller

http://www.w3.org/2001/XMLSchema#string

Kent T Sato

http://www.w3.org/2001/XMLSchema#string

Laura M Kulik

http://www.w3.org/2001/XMLSchema#string

Mary F Mulcahy

http://www.w3.org/2001/XMLSchema#string

Michael Abecassis

http://www.w3.org/2001/XMLSchema#string

Paul Nikolaidis

http://www.w3.org/2001/XMLSchema#string

Ramona Gupta

http://www.w3.org/2001/XMLSchema#string

P2860

The Measurement of Observer Agreement for Categorical Data

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

Survival analysis Part III: multivariate data analysis -- choosing a model and assessing its adequacy and fit.

Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation.

Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization

Hepatocellular carcinoma and hepatitis C in the United States.

P304

1062-1069

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2010.262

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

303

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42108900

http://www.w3.org/2001/XMLSchema#string

P698

20233824

http://www.w3.org/2001/XMLSchema#string

P932

3117395

http://www.w3.org/2001/XMLSchema#string